Eastman received RecyClass Recyclability Approvals for eight copolyester resins and their equivalent Renew grades, containing ...

There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.

2025 is set to be a game-changing year for cancer research, with cutting-edge therapies and technologies driving unprecedented progress in oncology.

The carrier expects an adjusted loss of between 40 cents and 20 cents per share, steeper than the 4 cents per share loss estimated by Wall Street.

MEPs from the left side of the European Parliament dislike Polish Prime minister’s attitude on migrations and the Green Deal, ...

The Arc of Greater Haverhill-Newburyport recently announced it received another $10,000 grant from the Doug Flutie, Jr.

To the editor: ...

Dividend stocks are a favorite among investors for good reason. They provide a steady income stream of passive income and ...